低剂量溴隐亭治疗帕金森病：双盲、安慰剂对照研究。
Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study.
作者信息
Staal-Schreinemachers A L, Wesseling H, Kamphuis D J, vd Burg W, Lakke J P
出版信息
Neurology. 1986 Feb;36(2):291-3. doi: 10.1212/wnl.36.2.291.
PMID:3511405
Abstract
Twenty-one de novo parkinsonian patients in stage I to III of the Hoehn and Yahr scale completed a 6-month, double-blind, placebo-controlled study. Low-dose bromocriptine (15 mg daily) was effective. Rigidity improved more than tremor or bradykinesia. Sustained satisfactory benefit was seen only in patients with mild Parkinson's disease.
摘要
21名处于Hoehn和Yahr分级I至III期的初发帕金森病患者完成了一项为期6个月的双盲、安慰剂对照研究。低剂量溴隐亭（每日15毫克）有效。僵直症状的改善比震颤或运动迟缓更明显。仅在轻度帕金森病患者中观察到持续的满意疗效。
Zotero 插件